All In Biotech

Drug Trial Radar · NCT07657273

Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma

A Prospective, Open-Label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of NRT6003 Injection (Yttrium-90 Carbon Microspheres) Radioembolization in Previously Treated Patients With Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Dec 21, 2027

Study completion Dec 21, 2027

Sponsor

Lead sponsor
Second Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single-arm, investigator-initiated study designed to evaluate the safety and efficacy of NRT6003 Injection, a yttrium-90 carbon microsphere product, administered by selective internal radiation therapy in previously treated patients with hepatocellular carcinoma. Eligible participants will undergo protocol-specified screening assessments, hepatic vascular evaluation, 99mTc-MAA hepatic arterial perfusion imaging, and dosimetry assessment before treatment. Participants who meet the eligibility criteria and are considered suitable for selective internal radiation therapy will receive a single transarterial administration of NRT6003 Injection. Safety follow-up will be conducted for 12 months after treatment, and tumor response will be assessed using mRECIST and RECIST v1.1.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • NRT6003 InjectionDrug

    NRT6003 Injection contains yttrium-90 carbon microspheres and is administered by transarterial infusion for selective internal radiation therapy. Participants will receive one treatment session only. The administered activity will be determined based on hepatic vascular assessment, 99mTc-MAA simulation, lung shunting assessment, and individualized dosimetry.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Assessed by mRECISTTime frame: Up to 12 months after NRT6003 administration
  2. Incidence, Type, and Severity of Adverse Events and Serious Adverse EventsTime frame: From hepatic vascular evaluation through 12 months after NRT6003 administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital, Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.